ProQR Therapeutics
PRQR
69 hedge funds and large institutions have $56.8M invested in ProQR Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
6% more funds holding
Funds holding: 65 → 69 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.01% less ownership
Funds ownership: 35.31% → 33.3% (-2%)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
24% less capital invested
Capital invested by funds: $75.1M → $56.8M (-$18.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$600K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
+$333K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$197K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$190K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.35M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$807K |
| 3 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
-$688K |
| 4 |
Millennium Management
New York
|
-$395K |
| 5 |
SCM
Sio Capital Management
New York
|
-$343K |
PRQR Hedge Fund Activity: Q1 2026 in Review
69 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2026, worth a combined $56.8M — down 24% from $75.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PRQR positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 16 trimmed.
The largest buyer was Aberdeen Group, adding an estimated $600K. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $2.35M sold.
- 69 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2026, up from 65 in Q4 2025.
- Funds reported $56.8M of ProQR Therapeutics stock for Q1 2026, down 24% quarter-over-quarter.
- 10 funds opened new ProQR Therapeutics positions in Q1 2026 and 6 closed out, a net change of +4 holders.
- The largest ProQR Therapeutics buyer in Q1 2026 was Aberdeen Group, an estimated $600K added.
- The largest ProQR Therapeutics seller in Q1 2026 was ArrowMark Colorado Holdings, an estimated $2.35M sold.
Based on aggregated 13F filings for Q1 2026.